Monday, June 3, 2019, Chicago, Illinois, 7:00 PM - 9:30 PM

Interactive Tumor Panel: Clinical Investigators Discuss Emerging Research and Actual Cases of Patients with Breast Cancer

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Fabrice André, MD, PhD
Research Director, Head of INSERM U981
Professor, Department of Medical Oncology
Institut Gustave Roussy
Villejuif, France

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair
in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas

Mark D Pegram, MD
Susy Yuan-Huey Hung Professor of Medicine
Director of the Breast Oncology Program
Associate Dean, Clinical Research Quality
Associate Director for Clinical Research
Stanford Cancer Institute
Stanford University School of Medicine
Stanford, California

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical
Trials Education
University of California, San Francisco
Medical Center
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, California

Sara M Tolaney, MD, MPH
Associate Director, Susan F Smith Center for Women’s Cancers
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Tiffany A Traina, MD
Clinical Director and Associate Attending
Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College
New York, New York

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech, Genomic Health Inc, Lilly, Merck, Puma Biotechnology Inc and Seattle Genetics.
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:30 PM — Educational Meeting

Meeting Agenda and Format

To begin each module one of the faculty will present an instructive case from his or her practice to frame a handful of educational issues and allow the panel to describe how they currently think through these situations. Members of the audience will be invited to use the iPads provided to participate in interactive polling related to the cases and issues being discussed. Another faculty member will then deliver a presentation during which he or she will review relevant data sets and ongoing trials related to the clinical scenarios under review, which will be followed by moderated panel discussion.

MODULE 1: Available and Emerging Data Sets Shaping the Management of Localized HER2-Positive Breast Cancer (BC) — Dr Rugo

  • Design, eligibility criteria and patient accrual for the Phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for patients with HER2-positive primary BC and residual disease after preoperative therapy
  • Key efficacy and safety results from the KATHERINE trial; clinical and research implications of the recent FDA approval of this approach
  • Safety profile of T-DM1 versus trastuzumab documented in the KATHERINE trial
  • FDA approval and patient selection for pertuzumab as part of adjuvant treatment; indications for adjuvant pertuzumab for patients receiving it as part of neoadjuvant therapy
  • Optimal integration of postadjuvant neratinib into clinical algorithms; patient selection and clinical factors guiding its use in practice

MODULE 2: Use of Genomic Classifiers in Clinical Decision-Making for Patients with ER-Positive Early BC — Dr Kaklamani

  • Design, eligibility criteria, primary and secondary endpoints and major clinical findings from the Phase III TAILORx intermediate-risk cohort
  • Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with early BC
  • Utility of other genomic classifiers beyond the 21-gene Recurrence Score® assay in ER-positive early BC
  • Updates to NCCN guidelines on the prioritization and role of genomic assays in node-negative and node-positive, ER-positive early BC
  • Use of genomic assays in clinical decision-making for patients completing 5 years of adjuvant endocrine therapy

MODULE 3: Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic BC (mBC); Novel Agents and Strategies Under Evaluation in ER-Positive Disease — Prof André

  • Research data with and current clinical role of CDK4/6 inhibitors for premenopausal, postmenopausal and elderly patients with ER-positive mBC
  • Incidence and severity of toxicities with palbociclib, ribociclib or abemaciclib in pivotal trials
  • Active clinical trials evaluating novel CDK4/6 inhibitor combinations in earlier disease settings
  • Incidence of mutations in phosphatidylinositol-3 kinase (eg, PIK3CA) in patients with hormone receptor-positive mBC
  • Design, eligibility and key efficacy and safety findings of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant for men and postmenopausal women with ER-positive, HER2-negative mBC with PIK3CA mutations; potential clinical role and optimal side-effect management

MODULE 4: Immunotherapy as a Rational Therapeutic Strategy in BC — Dr Tolaney

  • Early research experience with anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy for HER2-negative mBC
  • Design, eligibility criteria and patient accrual for the Phase III IMpassion130 trial evaluating atezolizumab with nab paclitaxel as first-line therapy for triple-negative mBC
  • Immune-related and other adverse events with combination therapy on the IMpassion130 study
  • FDA approval of atezolizumab/nab paclitaxel for patients with PD-L1-positive unresectable locally advanced or metastatic triple-negative BC; integration of this approach into clinical practice
  • Ongoing Phase III evaluation of anti-PD-1/PD-L1 antibodies alone or with other systemic therapies for localized, locally advanced and metastatic BC

MODULE 5: Protocol and Off-Protocol Decision-Making for Patients with HER2-Positive mBC — Dr Pegram

  • Published and ongoing investigations of neratinib/capecitabine for patients with HER2-positive mBC, including those with CNS metastases
  • Mechanism of action of tucatinib, a small molecule inhibitor selective for HER2: Associated CNS permeability and related activity in patients with HER2-positive brain metastases
  • Activity and safety of tucatinib with trastuzumab/capecitabine in patients with HER2-positive mBC; ongoing pivotal Phase II HER2CLIMB trial of trastuzumab/capecitabine with or without tucatinib
  • Structural makeup of and early efficacy and safety with the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive mBC; FDA breakthrough therapy designation and emerging data from the Phase II DESTINY-Breast01 trial
  • Emerging results from the Phase III SOPHIA trial comparing margetuximab/chemotherapy to trastuzumab/chemotherapy for HER2-positive mBC

MODULE 6: Role of PARP Inhibitors, Novel Agents in mBC; Male Breast Cancer — Dr Traina

  • Phase III data sets supporting the FDA approvals for olaparib (OlympiAD) and talazoparib (EMBRACA) for patients with mBC and a BRCA germline mutation
  • Available data with and ongoing evaluation of other PARP inhibitors (eg, veliparib, niraparib) in BC
  • Novel agents and strategies under development for triple-negative BC
  • Male breast cancer: A disease distinct from female breast cancer

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer (BC).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Consider published data to guide the use of biomarkers and genomic classifiers in assessing risk and customizing therapy for patients with hormone receptor-positive BC in the adjuvant and extended adjuvant settings.
  • Appraise available and emerging research evidence to individualize the selection and duration of neoadjuvant, adjuvant and extended adjuvant therapy for patients with HER2-overexpressing early BC.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptorpositive pre- and postmenopausal BC, including endocrine, biologic and chemotherapeutic agents.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive BC, incorporating existing and investigational targeted treatments.
  • Appraise published efficacy and safety data with the use of PARP inhibitors for patients with metastatic BC harboring a BRCA1/2 mutation, and consider the diagnostic and therapeutic implications of these findings on nonresearch care.
  • Appraise recently presented Phase III data supporting the FDA approval of anti-PD-L1 antibody therapy combined with chemotherapy for newly diagnosed PD-L1-positive metastatic triple-negative BC, and use this information to identify patients who may be appropriate for this approach in clinical practice.
  • Develop an understanding of the mechanisms of action of, available data with and potential clinical roles of other investigational compounds to facilitate referral for clinical trial opportunities or participation in expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech, Genomic Health Inc, Lilly, Merck, Puma Biotechnology Inc and Seattle Genetics.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.


Thank you for your interest in our educational program. At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM on Monday, June 3rd. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients, and meal service will be offered based on availability. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.